Tauber J, Wirta DL, Sall K, Majmudar PA, Willen D, Krösser S; SEECASE study group. A Randomized Clinical Study (SEECASE) to Assess Efficacy, Safety, and Tolerability of NOV03 for Treatment of Dry Eye Disease. Cornea. 2021 Sep 1;40(9):1132-1140(一项旨在评估NOV03治疗干眼症的效果、安全性和耐受性的随机临床研究(SEECASE)。《角膜》。2021年9月1日;40(9):1132-1140)
Tian L, Gao Z, Zhu L, Shi X, Zhao S, Gu H, Xu G, Wang L, Dai H, Zhang H, Jin X, Ma K, Xu Y, Ma L, Pei C, Ke B, Krösser S, Zhang Y, Jie Y. Perfluorohexyloctane Eye Drops for Dry Eye Disease Associated With Meibomian Gland Dysfunction in Chinese Patients: A Randomized Clinical Trial. JAMA Ophthalmol. 2023 Apr 1;141(4):385-392(全氟己基辛烷滴眼液治疗伴有睑板腺功能障碍的中国干眼症患者:一项随机的临床试验。《眼科学纪要》。2023年4月1日;1;141(4):385-392)
Tauber J, Berdy GJ, Wirta DL, Krösser S, Vittitow JL; GOBI Study Group. NOV03 for Dry Eye Disease Associated with Meibomian Gland Dysfunction: Results of the Randomized Phase 3 GOBI Study. Ophthalmology. 2023 May;130(5):516-524(NOV03治疗伴睑板腺功能障碍的干眼症:随机3期GOBI研究的结果。《眼科学》。2023年5月;130(5):516-524)
Sheppard JD, Kurata F, Epitropoulos AT, Krösser S, Vittitow JL; MOJAVE STUDY GROUP. NOV03 for Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction: the Randomized Phase 3 MOJAVE Study: NOV03 for Dry Eye Disease Associated With Meibomian Gland Dysfunction (69 characters; limit, 60). Am J Ophthalmol. 2023 Mar 20: S0002-9394(23)00098-3(NOV03用于伴睑板腺功能障碍的干眼病体征和症状:随机第3期MOJAVE研究:NOV03用于伴睑板腺功能障碍的干眼病。《美国眼科杂志》。2023年3月20日:S0002-9394(23)00098-3)